The Regulatory Reality of 2026: What Actually Changed In late 2023, the FDA moved 19 peptides, including BPC-157, to what's known as "Category 2" status under its framework for bulk drug substances used in compounding, identifying them as substances that "may present significant safety risks." The concern, as stated in FDA guidance, centered on the limited large-scale human data and questions about immunogenicity
1 Comorbidities include high blood pressure, type 2 diabetes, high cholesterol, osteoarthritis or other joint/muscle issues, liver disease, heart disease, polycystic ovary syndrome (PCOS) and low testosterone
Mild nausea at 1 mg becomes moderate nausea at 2 mg and potentially severe nausea at 4 mg
While they all offer access to GLP-1 treatments, the experience, structure, and approach differ significantly
A liposome is a tiny, fatty sphere called a phospholipid bilayerthe same material that makes up your own cell membranes